7 drugs likely to hit $1B in annual revenue in the next 5 years

Listen
Text
  • Small
  • Medium
  • Large

Seven new drugs are expected to reach $1 billion in annual revenue in the next five years, according to a report issued Jan. 10 by analytics firm Clarivate.

Six of the drugs are awaiting FDA approval, and one (tezepelumab) just won approval. Here is a list:

  1. Adagrasib: a drug designed to treat colorectal cancer with the KRASG12C mutation, produced by Mirati Therapeutics and Zai Lab.

  2. Donanemab: a drug designed to slow cognitive decline, produced by Eli Lilly.

  3. Faricimab: a drug designed to treat patients with diabetic macular edema or wet age-related macular degeneration, produced by Roche and Chugai Pharmaceutical.

  4. Lecanemab: a drug designed to slow cognitive decline, produced by Eisai and Biogen.

  5. Tezepelumab: an asthma drug produced by Amgen and AstraZeneca.

  6. Tirzepatide: a drug designed to address weight loss and glycemic control, produced by Eli Lilly.

  7. Vutrisiran: a drug designed to treat ATTR, produced by Alnylam Pharmaceuticals.

Copyright © 2022 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Whitepapers

Featured Webinars